The medical consensus is that prenatal dexamethasone for CAH should only be pursued within prospective clinical trials that are “approved by Institutional Review Boards at centers capable of collecting outcomes data on a sufficiently large number of patients so that risks and benefits of this treatment can be defined more precisely.” This consensus was published in 2010 by the Endocrine Society and was co-sponsored by the American Academy of Pediatrics, the Androgen Excess and PCOS Society, the CARES Foundation, the European Society of Endocrinology, the European Society for Paediatric Endocrinology, the Pediatric Endocrine Society, and the Society of Pediatric Urology. You can read the consensus in section 2.0 of the article linked in PDF form here.
Posted in: Medical Care